Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Video Library

View video lectures on hot topics, challenging cases, and recent advances in psoriasis management presented by key opinion leaders in the field of psoriasis. Presentations and videos are curated from some of the most respected dermatologists in the world and are available at no-cost to clinicians. 

Biologics

Management of psoriasis with biologics during the COVID-19 pandemic

Biologics, COVID-19, Take Ten 2021

Paolo Gisondi, MD | Italy

View

The psoriasis pipeline: Upcoming new systemic drugs

Biologics, Take Ten 2021

Andrew Blauvelt, MD, MBA | USA

View

Management of psoriasis with biologics during the COVID-19 pandemic – Italian

Biologics, Take Ten 2020

Paolo Gisondi, MD | Italy

View

Psoriasis: Risk of infections during conventional and biologic therapy

Biologics, Take Ten 2020

Ricardo Romiti, MD, PhD | Brazil

View

News about psoriasis in Egypt

Biologics 2020

Mahira Hamdy El Sayed, MD | Egypt
Cairo Masterclass

View

Psoriasis updates in a nutshell

Biologics, Topical therapies 2020

Mohamed El-Komy, MD | Egypt
Cairo Masterclass

View

Optimizing the use of biologics

Biologics 2019

April Armstrong, MD, MPH | USA 

View

Drug survival and the sequential use of biologics

Biologics 2019

Lone Skov, MD, PhD | Denmark
EADV | Madrid, Spain

View

Search Reviews:

Filter by Topic:


Latest news

March 30, 2021
Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor.
March 29, 2021
Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study.
March 28, 2021
Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.
March 17, 2021
Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases.
  More News
We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK